BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

31 related articles for article (PubMed ID: 10740632)

  • 1. Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the U.K.
    Sweetenham J; Hieke K; Kerrigan M; Howard P; Smartt PF; McIntyre AM; Townshend S
    Br J Haematol; 1999 Jul; 106(1):47-54. PubMed ID: 10444162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial.
    Watanabe T; Tobinai K; Shibata T; Tsukasaki K; Morishima Y; Maseki N; Kinoshita T; Suzuki T; Yamaguchi M; Ando K; Ogura M; Taniwaki M; Uike N; Takeuchi K; Nawano S; Terauchi T; Hotta T
    J Clin Oncol; 2011 Oct; 29(30):3990-8. PubMed ID: 21931035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [B-cell lymphoma developing de novo hepatitis B after salvage therapies including rituximab through seroconversion of surface antibody].
    Ishihara T; Kanagawa M; Koyama J; Hasegawa K; Suzuki T; Hirayama Y; Terui T
    Rinsho Ketsueki; 2014 Nov; 55(11):2283-7. PubMed ID: 25501408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Standard CHOP immuno-chemotherapy for primary mediastinal lymphomas].
    Schneider T; Tóth E; Lovey J; Molnár Z; Deák B; Várady E; Csomor J; Matolcsy A; Lengyel Z; Petri K; Gaudi I; Rosta A
    Orv Hetil; 2011 May; 152(19):735-42. PubMed ID: 21498163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New combination therapies in hematological malignancies].
    Takeshita A; Ohno R
    Gan To Kagaku Ryoho; 2000 Mar; 27(3):388-94. PubMed ID: 10740632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hematological malignancies].
    Usui N
    Gan To Kagaku Ryoho; 2007 Mar; 34(3):358-66. PubMed ID: 17353625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunochemotherapy in indolent non-Hodgkin's lymphoma.
    Czuczman MS
    Semin Oncol; 2002 Apr; 29(2 Suppl 6):11-7. PubMed ID: 12040529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.
    Czuczman MS; Fallon A; Mohr A; Stewart C; Bernstein ZP; McCarthy P; Skipper M; Brown K; Miller K; Wentling D; Klippenstein D; Loud P; Rock MK; Benyunes M; Grillo-López AJ; Bernstein SH
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):36-40. PubMed ID: 11842387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of aggressive non-Hodgkin's lymphoma: a north American perspective.
    Sehn LH; Connors JM
    Oncology (Williston Park); 2005 Apr; 19(4 Suppl 1):26-34. PubMed ID: 15934515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rituximab, a chimeric mouse-human anti-CD20 monoclonal antibody].
    Tobinai K
    Nihon Rinsho; 2002 Mar; 60(3):468-72. PubMed ID: 11904960
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.